Men who already carry the genetic profile for the most common form of baldness have roughly a 7 percent added risk of losing their hair when GLP-1 receptor activity is higher, according to research from NYU Langone Health published Thursday in the Journal of Investigative Dermatology. The researchers describe it as the first genetic evidence connecting the biology behind drugs like Ozempic, Wegovy and Zepbound to male pattern hair loss.
The distinction matters for anyone reading the headline and reaching for a prescription bottle. Researchers did not follow patients taking these medications and count how many lost hair. They compared genetic data, using the GLP1R gene as a stand-in for the drugs' biological effect, and looked for overlap with the genes found in men who have androgenetic alopecia.
That design answers a different question than most people assume. It suggests the two things are biologically linked rather than coincidentally connected. It does not measure how many people on a prescription will actually notice thinning, or how severe that thinning would be. For the estimated 12 percent of Americans who have used a GLP-1 drug for weight loss alone, that gap is the difference between a reason to ask a question and a reason to stop treatment.
A Genetic Signal Standing In for a Prescription
The work was led by senior investigator Lynn Petukhova, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine. The team drew on two large public genetic databases: the eQTLGen database covering 31,684 men and women, and a Complex Traits Genetics group database covering 205,327 men. Both are made up mostly of White participants.
The GLP1R gene naturally raises the body's levels of GLP-1 receptor proteins. More receptor activity was treated as a proxy for what the drugs do pharmacologically. Men whose genes produced higher receptor activity turned out to be more likely to also carry the genetic signature of androgenetic alopecia, the inherited pattern that recedes along the top and front of the scalp.
Male hair loss is far better characterized genetically than female hair loss, which is why the analysis could only be run in men. Whether the same relationship holds for women remains an open question, and Petukhova said she plans to investigate it.
The Number Held Up Against Three Alternative Explanations
The most useful part of the analysis is what the researchers ruled out. Hair loss has several known drivers that could have muddied the signal, and each one was tested.
They first adjusted for high blood pressure, which is thought to reduce blood flow to the scalp and damage follicle growth. The 7 percent figure did not move. They then checked insulin resistance, a cause of type 2 diabetes and a plausible confounder given who takes these drugs. They also checked lowered testosterone. In every case, the added risk stayed at 7 percent.
That consistency is what allows the authors to describe a biological link rather than a statistical coincidence. It still does not establish that a specific patient on a specific dose will shed hair, and it says nothing about how long any shedding would last.
Scale is part of why the question matters now. Survey data cited by NYU Langone suggest that about one in five women aged 50 to 64 has used one of these medications for weight loss, and prescribing has expanded sharply in recent years.
Existing clinical evidence remains mixed. A systematic review in the International Journal of Dermatology examining more than 920,000 adverse event reports found hair loss reported in about 1.6 percent of patients taking these drugs, with a far smaller group reporting regrowth. Reviewers noted that causality could not be inferred from pharmacovigilance data.
Financial Ties and Population Limits Belong Beside the Result
Two limitations sit close to the surface of this study and should travel with the headline.
The genetic databases used were composed mostly of White participants. Androgenetic alopecia is estimated to affect half of White American men over 50, and the prevalence and genetic architecture in other populations are less well mapped. Applying a 7 percent figure across all men would overstate what the data can support.
Financial relationships also warrant disclosure. The study was funded by National Institutes of Health grants. Two NYU Langone co-investigators, Jerry Shapiro and Kristen Lo Sicco, have previously served as study investigators for hair loss drugs and devices made by Pfizer and Regen Labs. Lo Sicco is a paid consultant for Pfizer, Lilly, Ro, Priovant, Veradermics and Aquis. NYU Langone says those relationships are managed under institutional policy. None of that invalidates the genetics, but readers weighing a finding about hair loss treatment should know who advises whom.
Petukhova framed the practical value carefully, saying in the NYU Langone announcement that if future experiments succeed, "some men, and possibly women too, could be screened and benchmarked for their risk" before being prescribed these drugs. She added that combination treatments such as minoxidil could eventually be prescribed alongside them. Neither approach exists in clinical practice today.
Reasonable Questions to Bring to a Prescriber
Nobody should stop a diabetes or obesity medication over a genetics paper. Rapid weight loss itself triggers a common temporary shedding pattern called telogen effluvium, and hair growth typically resumes once weight stabilizes.
People who are noticing thinning can ask a clinician whether the timing fits rapid weight loss, whether iron, zinc, protein or vitamin D levels have dropped, and whether family history points toward pattern baldness that would have progressed anyway. Anyone considering a hair loss treatment should raise it with a dermatologist rather than an online seller, a caution that also applies to the counterfeit weight loss vials federal screeners have flagged at the border.
The research team says further work is needed to explain the mechanism connecting GLP-1 activity to weakened follicle growth, and to test whether the pattern extends to women. Men weighing hormone-related treatments for other reasons face a similar evidence gap, as MedicalDaily has reported on testosterone therapy. Current prescribing guidance has not changed.
Key Questions Answered
Does this study prove GLP-1 drugs cause hair loss? No. It used a gene that raises GLP-1 receptor activity as a proxy for the drugs and found genetic overlap with male pattern baldness. It did not track patients on prescriptions or measure how often they lost hair.
What does a 7 percent added risk actually mean? It applies on top of a man's existing genetic risk for androgenetic alopecia, not to every person taking the drug. It describes a population level signal, not an individual prediction.
Does this apply to women? The analysis was limited to men because male hair loss genetics are much better characterized. The lead researcher says she plans to study whether the link holds in women.
Should someone stop taking Ozempic, Wegovy or Zepbound? No one should stop a prescribed medication based on this research. Prescribing guidance has not changed. Concerns about thinning hair should be raised with the prescribing clinician.
Is hair loss on these drugs permanent? Much of the shedding reported by users appears to be telogen effluvium tied to rapid weight loss, which commonly resolves several months after weight stabilizes. A dermatologist can distinguish that from pattern baldness.
Who funded the research, and were there industry ties? The National Institutes of Health funded the study. Two NYU Langone co-investigators have had past or current paid relationships with pharmaceutical companies, disclosed in the study announcement and managed under institutional policy.
Are there approved treatments if hair loss occurs? Established options such as minoxidil exist for pattern hair loss, but no combination protocol specific to GLP-1 users has been tested or approved. That remains a research proposal.
